Navigation Links
Nanophase Announces Changes in Principal Officers and Directors
Date:3/3/2009

ROMEOVILLE, Ill., March 3 /PRNewswire-FirstCall/ -- Nanophase Technologies (Nasdaq: NANX), a technology leader in nanomaterials and advanced nanoengineered products, announced today that the Company accepted the resignation of Dr. Richard Brotzman, effective February 28th, as its Chief Technology Officer, so that he may pursue new entrepreneurial business opportunities. Dr. Brotzman was responsible for several of the Company's key patents and served as technical liaison to many of the Company's market partners, helping to bring Nanophase from a development stage company to a commercial enterprise.

The Company also accepted the resignation of Robert Haines, VP of Operations, effective February 28, 2009, who left the Company for health related reasons. Mr. Haines was the critical driver in the Company's progression towards developing the world-class quality-driven volume manufacturing platform that has become one of its key strengths.

Nanophase also announced that Jess Jankowski has been elevated to the position of President & Chief Executive Officer and board director, effective February 28, 2009. Mr. Jankowski had been Nanophase's Acting Chief Executive Officer since August of 2008. He will continue to serve also as Chief Financial Officer as the Company conducts a search for his replacement in that role. Don Perkins, the Company's Chairman, commented that "Mr. Jankowski has earned the Board's trust over the years and has impressed us with his vision for Nanophase and the team he has developed since he assumed leadership six months ago. It is reassuring to note that Mr. Jankowski and his team hold an average of 8 years experience with Nanophase."

Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leader in nanomaterials technologies and provides nanoengineered solutions for multiple industrial product applications. Using a platform of patented and proprietary integrated nanomaterial technologies, the Company creates products with unique performance attributes from two ISO 9001:2000 and ISO 14001 facilities. Nanophase delivers commercial quantity and quality nanoparticles, coated nanoparticles, and nanoparticle dispersions in a variety of media. Information about Nanophase may be found in the Company's public filings or on its website.

All numbers in this release are approximate; refer to the financials accompanying the release for details. Earnings per share are stated as fully diluted. This press release contains words such as "expects", "shall", "will" , "believes" and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risk and uncertainties include the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company's dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company's nanocrystalline materials; the Company's manufacturing capacity and product mix flexibility in light of customer demand; the Company's limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company's dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; and other risks described in the Company's Form 10K filed March 14, 2008, and other filings with the Securities and Exchange Commission. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.


'/>"/>
SOURCE Nanophase Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Announces 2008 Financial Results
2. IRIDEX Announces Fourth Quarter and Full Year 2008 Conference Call and Release Date
3. Misonix Announces New Sales Agency Agreement for Eastern Europe
4. Cambridge Healthtech Institute Announces Its Premiere Collaborative Innovation in Biomedicine Conference
5. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
6. Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)
7. FamilyLink.com, Inc. Announces New Lead Developer
8. Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation
9. American Psychiatric Foundation Announces Recipients of Helping Hands Grants
10. Acuo Technologies(R) Announces Another Record Sales and Implementation Growth
11. CorNova Announces Addition of Andrew T. Jay, D.M.D., M.B.A., to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... RYE, New York (PRWEB) , ... February 23, 2017 , ... ... to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, ... the 30 clinical sites already enrolling children across the United States. , “There ...
(Date:2/22/2017)... East Setauket, New York (PRWEB) , ... February ... ... the main floor entrance and lobby of a new healthcare contact center in ... gleaming results. , One of the nation’s largest healthcare systems recently invested $51 ...
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology: